Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway by Malsy, Manuela et al.
Malsy et al. Eur J Med Res            (2019) 24:5  
https://doi.org/10.1186/s40001-019-0365-x
RESEARCH
Staurosporine induces apoptosis 
in pancreatic carcinoma cells PaTu 8988t 
and Panc-1 via the intrinsic signaling pathway
Manuela Malsy*, Diane Bitzinger, Bernhard Graf and Anika Bundscherer
Abstract 
Background: Cancer, one of the leading causes of death worldwide, develops when the normal balance between 
mitosis and apoptosis is disrupted. The subsequently increased proliferation rate or decreased apoptosis rate of cells 
leads to uncontrolled cellular growth. Thus, the current aim of cancer research is to increase the apoptosis rate in 
tumor cells—while limiting the concurrent death of healthy cells—and to induce controlled apoptosis in abnormal 
cells. Staurosporine is a very potent inducer of apoptosis because it inhibits many different kinases. So far, many differ-
ent kinase pathways of staurosporine-induced apoptosis have been discussed for various tumor entities.
Aims: To identify the effect of staurosporine in pancreatic and colorectal carcinoma cells and its apoptosis-inducing 
signaling pathway.
Methods: The apoptosis rate in pancreatic and colorectal carcinoma cells was analyzed by annexin V staining after 
staurosporine administration. Staurosporine stimulation and its effects on the expression of Bcl2, BAX, Bad, caspase-8, 
and caspase-9 were investigated with immunoblot.
Results: Staurosporine significantly increased apoptosis in pancreatic carcinoma cells. Western blot analysis showed 
activation of caspase-9 in PaTu 8988t and Panc-1 cells with 1 µM staurosporine. In addition, expression of Bcl2 and 
Bad was decreased in PaTu 8988t cells. In colorectal carcinoma cells SW 480, staurosporine stimulation did not induce 
apoptosis.
Conclusion: Modern therapeutic strategies for tumor diseases target the efficient modulation of specific signaling 
and transcription pathways. In this respect, the therapeutic potential of protein kinase inhibitors has been repeatedly 
discussed. Our study showed that staurosporine induces apoptosis in pancreatic carcinoma cells via the intrinsic sign-
aling pathway. Thus, staurosporine is a suitable positive control for in vitro apoptosis tests for the pancreatic cancer 
cell lines PaTu 8988t and Panc-1. Further clinical studies should analyze the impact of this finding on cancer treatment.
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Background
Malignant tumors are one of the main scourges of 
humanity. In 2012 alone, about 8.2 million people died 
of carcinoma worldwide, and—according to the World 
Health Organization—[1] this figure is expected to rise to 
13 million over the next 20 years.
From the molecular biology point of view, cancer is 
defined as any type of malignant neoplasm, independ-
ent of the organ or the tissue from which the tumor 
originates [2]. Cancer develops when the normal balance 
between mitosis and apoptosis is disrupted [3]. The sub-
sequent increase in the proliferation rate or the decrease 
in the apoptosis rate of cells results in uncontrolled cellu-
lar growth [4, 5]. Thus, the current aim of cancer research 
is to increase the apoptosis rate in tumor cells—while 
simultaneously limiting concurrent death of healthy 
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cells—and to induce controlled apoptosis in abnormal 
cells [6].
Therefore, comprehensive knowledge of the mecha-
nisms of apoptosis in the different types of cells is vital 
for developing potential cancer therapies [7]. The term 
apoptosis refers to programmed cell death, which con-
stitutes an important mechanism for maintaining tis-
sue homeostasis [8]. The characteristic feature in this 
respect is that apoptosis is actively induced by the 
respective cell itself; thus, the cell is part of the metabo-
lism. Activation of proteolytic enzymes termed cas-
pases results in cellular shrinkage, condensation, and 
fragmentation of the cell nucleus, loss of cellular adhe-
sion, and finally in apoptosis [9]. Apoptosis is induced 
by activation of important signal-transduction cas-
cades [10]. Here, extrinsic and intrinsic signaling path-
ways have to be differentiated [11]. After the binding 
of a ligand to the death receptor of the tumor necrosis 
factor receptor family CD 95 (APO-1/Fas) or TRAIL 
receptors, caspase-8 is activated via the extrinsic sign-
aling pathway [12, 13]. In turn, caspase-8 activates cas-
pase-3 (effector caspase) [14], thus inducing apoptosis. 
The intrinsic signaling pathway is the cellular response 
to stress [15]. Changes in the mitochondrial mem-
brane result in the collapse of its potential and thus 
in the release of cytochrome C, which subsequently 
irreversibly instigates the entire caspase cascade by 
activating caspase-9 [16] (Fig. 1).
A highly potent inductor of apoptosis is stauro-
sporine, an alkaloid that inhibits many different kinases 
[17]. Several new derivatives of this substance, which 
was originally isolated from Streptomyces stauro-
sporeus, have been synthesized in clinical trials to be 
used in anticancer therapies [18]. So far, many different 
kinase pathways of staurosporine-induced apoptosis 
have been discussed for various tumor entities [19–21].
The aim of this study was to identify the effect of 
staurosporine in pancreatic and colorectal carcinoma 
cells and its apoptosis-inducing signaling pathway.
Methods
Cell lines
The human pancreatic adenocarcinoma cell lines PaTu 
8988t and Panc-1 were obtained from Professor Ellen-
rieder (Philipps University of Marburg, Germany). 
The colorectal carcinoma cell line SW 480 was pur-
chased from the German Collection of Microorgan-
ism and Cell Culture (DSMZ). PaTu 8988t and Panc-1 
cells were maintained in Dulbecco’s modified Eagle’s 
medium (Sigma-Aldrich, Steinsheim, Germany) or 
RPMI 1640 (Pan Biotech, Aidenbach, Germany), which 
was supplemented with 10% fetal calf serum (FCS) 
Fig. 1 Apoptotic signaling pathway. Caspase-8 is activated via the extrinsic signaling pathway by the binding of a ligand to the death receptor. 
The intrinsic signaling pathway is activated by changes in the mitochondrial membrane potential and the subsequent release of cytochrome C, 
which influences the pro-apoptotic factors BAK, Bad, and BAX as well as the anti-apoptotic factors Bcl2 and Bcl-xl and thus triggers caspase-9. Both 
pathways merge into a common pathway, in which effector caspase-3 finally induces apoptosis
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(Sigma-Aldrich) and 5% Myco Zap (Lonza Verviers 
SPRL, Verviers, Belgium) or 5% penicillin plus strepto-
mycin (Sigma-Aldrich) for SW 480. Cells were cultured 
at 37 °C in humidified  CO2 atmosphere (5%) and main-
tained in monolayer culture. Experiments were done 
with cells at ~ 70–80% confluence.
Antibodies and reagents
Staurosporine was purchased from Sigma-Aldrich. 
Final concentrations were achieved by diluting drugs 
in standard growth media. All solutions were pre-
pared freshly prior to use. For immunoblotting, mem-
branes were probed with antibodies against Bcl2, BAX, 
Bad, caspase-8, caspase-9 (cell signaling), and ß-actin 
(Sigma-Aldrich).
Subcellular fractionation and immunoblotting
Cells were washed twice with cold DPBS and col-
lected by centrifugation at 4000 rpm at 4 °C for 10 min. 
Lysates were then resuspended in RIPAE-buffer (5 mL 
Triton X-100, 190  mg EDTA, 0.5  g SDS, 2.5  g deoxy-
cholic acid, 500  mL DPBS, protease inhibitors) for 
15 min and centrifuged at 13,000 rpm for 30 min. The 
supernatants were transferred to new cups and incu-
bated on ice. 30  µg of the total lysates were analyzed 
by SDS-PAGE and blotted onto nitrocellulose. After 
protein extraction and gel transfer, the membranes 
were washed in TBS washing buffer and incubated with 
peroxidase-conjugated secondary antibodies. Immu-
noreactive proteins were visualized by means of an 
enhanced chemiluminescence detection system (West-
ern Blotting Detection Reagent, GE Healthcare).
Apoptosis analysis
Apoptosis assays by annexin V staining were conducted 
according to the manufacturer’s instructions (BD 
Pharming). In brief, PaTu 8988t, Panc-1, and SW 480 
cells were incubated with 1 µM of staurosporine. Stand-
ard growth medium was used for negative control. 
After 0 h, 3 h, 6 h, 9 h, 12 h, 16 h, or 24 h incubation 
time, the supernatant was decanted from the cells to 
preserve floating cells. Adherent cells were rinsed with 
warm PBS (Sigma-Aldrich) and harvested by standard 
trypsinization. Afterward, harvested and floating cells 
were mixed, washed, and resuspended in binding buffer 
at a final concentration of 106  cells/ml. 100  µL of cell 
suspension containing 105 cells was resuspended in 
5  µL of FITC Annexin plus 5  µL of propidium iodide, 
followed by 15  min incubation at room temperature 
protected from light. The cells were washed and resus-
pended with 400 µL of binding buffer. Finally, the cells 
were analyzed by flow cytometry using FACS Calibur 
(BD Bioscience) and CellQuest Pro software (BD Bio-
science). All tests were done in duplicate and the pro-
cess was repeated twice.
Statistical analysis
Data are presented as mean ± SD. The non-parametric 
Mann–Whitney U test was used for statistical evalua-
tion of the data. P values < 0.05 were considered signifi-
cant. IBM SPSS Statistics (Vs. 20; IBM New York, US) 
and Excel Vs. 2010 (Microsoft, Redmond, USA) packages 
were employed for statistical analysis.
Results
Analysis of apoptosis and necrosis
The annexin V staining apoptosis assay was used to deter-
mine whether incubation with staurosporine induced 
apoptosis or necrosis. Incubation with staurosporine 
for 6  h (Fig.  2a) increased the vital cell fraction phase 
of colorectal carcinoma cells SW 480 to 84.75% ± 3.57% 
compared to the untreated samples. No other significant 
changes in apoptosis rate or cell death behavior were 
observed during any of the other time frames.
In contrast to the untreated control samples in the pan-
creatic cancer cell line PaTu 8988t, incubation with stau-
rosporine between 3  h and 24  h significantly increased 
the rate of apoptosis (Fig.  2b) and significantly reduced 
the number of vital cells. The necrosis rate was increased 
after 6 h, 12 h, and 16 h incubation. In Panc-1, stimula-
tion with staurosporine (Fig.  2c) significantly increased 
apoptosis and significantly reduced the number of vital 
cells after 9 h, 12 h, 16 h, and 24 h.
Endogenic expression of Bcl2, Bad, BAX, caspase‑8, 
and caspase‑9 in pancreatic and colorectal carcinoma cells
The first aim was to obtain evidence for the actual expres-
sion of Bcl2, Bad, BAX, caspase-8, and caspase-9 in 
pancreatic and colorectal carcinoma cells (Fig.  3). The 
pancreatic cancer cell line PaTu 8988t (column 2) showed 
strong expression of each of the proteins investigated, 
whereas the cell lines SW 480 and Panc-1 showed only 
expression of BAX, caspase-8, and caspase-9. The proteins 
Bcl2 and Bad could not be detected at all. The endogenous 
expression of ß-actin serving as loading control can be seen 
in the lower blot (column 6).
Western blot analysis after time‑dependent incubation 
with 1 µM staurosporine and endogenic expression 
of Bcl2, BAX, Bad, caspase‑8, and caspase‑9 in pancreatic 
and colorectal carcinoma cells
The colorectal cancer cell line SW 480 did not show any 
time-dependent changes in the expression of the pro-
teins BAX, caspase-8, and caspase-9 (Fig. 4a). The pan-
creatic cancer cell line PaTu 8988t (Fig.  4b) showed a 
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time-dependent decrease in the signal strength of Bcl2 
after incubation with staurosporine up to the complete 
absence of proteins after 24 h of incubation (column 1). 
In contrast, expression of BAX and caspase-8 was not 
influenced by staurosporine; here, only the band inten-
sity was decreased after 24  h of incubation (column 2 
and 4). Expression of Bad was considerably decreased 
after 3  h and 6  h of incubation in the reagent in con-
trast to untreated cells only incubated in the medium. 
After 9  h of incubation, protein was no longer detect-
able (column 3).
Use of the antibody caspase-9 enabled detection of 
full length caspase-9 as well as cleaved caspase-9. The 
control samples, which had only been incubated in the 
medium, showed considerable signal strength for full 
length caspase-9 that was markedly decreased after 3 h 
and 6  h of incubation with staurosporine. At the later 
time points (9 h to 24 h of incubation), protein was no 
Fig. 2 The effects of staurosporine on apoptosis in in vitro SW 480 colorectal carcinoma (a) and PaTu 8988t (b) and Panc-1 (c) pancreatic carcinoma 
cell lines after time-dependent incubation. For apoptosis analysis, cancer cells were stained with annexin V. (*) indicates statistical significance at 
p < 0.05 compared to untreated control
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longer detectable. In contrast, expression of cleaved 
caspase-9 first increased after incubation with stauro-
sporine, showing the maximum signal strength after 6 h 
of incubation, but steadily decreased over the later time 
points (column 5). Column 6 depicts the endogenous 
expression of ß-actin that served as loading control.
In the pancreatic cancer cell line Panc-1 (Fig. 4c), BAX 
expression was not influenced by incubation with stau-
rosporine (column 1), whereas the signal strength of 
caspase-8 steadily increased in a time-dependent man-
ner (column 2). Expression of full length caspase-9 
decreased, but expression of cleaved caspase-9 increased 
after stimulation with the reagent. After 24 h of incuba-
tion, the signal strength of both bands was decreased. 
Column 4 depicts the endogenous expression of ß-actin 
that served as loading control.
Discussion
Apoptosis is a key regulator of physiological growth 
control and tissue homeostasis. One of the most impor-
tant findings in cancer research of the past few years is 
that apoptosis has a high impact on the development 
of tumors as well as on their response to chemotherapy 
[22, 23]. Bcl2 proteins residing on the mitochondrial 
membrane serve a regulatory function in the intrinsic 
apoptotic signaling pathway. They strictly control this 
pathway by inducing mitochondrial outer membrane 
permeabilization (MOMP). All proteins of the family 
show similar structural domains, called “Bcl2 homol-
ogy (BH) domains” (named BH1, BH2, BH3, and BH4). 
They can be divided into three subgroups: the prosur-
vival members (Bcl2, Bcl-xl, Bcl-w, MCL-1, and A1), the 
pro-apoptotic members, which include the MOMP effec-
tors (mainly BAX and BAK), and the BH3-only proteins, 
so called because they have only the BH3 domain (Bad, 
BIM, BID, PUMA, NOXA) [24].
Pro-apoptotic factors such as BAX, BAK, and Bad and 
the anti-apoptotic factors Bcl2 and Bcl-xl are delicately 
balanced, and this balance is often lacking in tumor cells 
[25]. For instance, dysfunction of BAX may further the 
tumor genesis of cells; thus, many chemotherapies try to 
indirectly intervene in this process [26]. Derivatives such 
as oblimersen sodium, AT-101, ABT-263, and GX15-070 
are currently under clinical investigation [27, 28]. Fur-
thermore, kinase inhibitors are also constantly used in 
cancer treatment [29, 30].
A highly potent inductor of apoptosis is staurosporine, 
an alkaloid that inhibits many different kinases [17]. In 
2001, Stepczynska et al. [18] showed that staurosporine—
as a broadband kinase inhibitor—induced apoptosis in 
Jurkat cells resistant to chemotherapeutic agents. Chae 
et  al. [31] reported on the apoptosis-inducing effect of 
staurosporine in osteoblasts and Xue et  al. [32] on this 
effect in breast carcinoma cells. The inhibiting effect of 
staurosporine on cell adhesion, mobilization, and inva-
sion could also be shown in lung carcinoma cells [33]. 
To different degrees, staurosporine also seems to affect 
the induction of apoptosis in pancreatic and colorec-
tal carcinoma cells. However, the signaling pathway by 
which staurosporine induces apoptosis has yet remained 
unclear.
The current study shows that—in the pancreatic and 
colorectal cancer cell lines Panc-1, PaTu 8988t, and SW 
480—staurosporine does not influence BAX, but influ-
ences the anti-apoptotic factor Bcl2. The Bcl2 protein 
is often overexpressed in several types of cancer, for 
instance in breast, lung, and ovarian cancer or in malig-
nant melanoma. Therefore, evidence of Bcl2 in cells is 
often associated with unfavorable outcome [34].
Bcl2 is expressed in the pancreatic cancer cell line PaTu 
8988t. If Bcl2 is produced, apoptosis may be induced 
by suppressive medication. For this reason, the effect of 
BH3-mimetica has been repeatedly investigated in clini-
cal trials, because these drugs induce apoptosis by bind-
ing and inhibiting anti-apoptotic members of the Bcl2 
protein family [35, 36].
However, Bcl2 expression decreased after the admin-
istration of staurosporine in PaTu 8988t carcinoma cells. 
But why does staurosporine, as a kinase inhibitor, cause 
Fig. 3 Immunblotting and proof of endogenic expression of Bcl2, 
BAX, Bad, caspase-8, caspase-9, and ß-actin in colorectal cancer cells 
(SW 480) and pancreatic cancer cells (PaTu 8988t and Panc-1)
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activation of the intrinsic apoptotic pathway? A pos-
sible explanatory approach could be that the imbalance 
between BAX and Bcl2—thus between pro-apoptotic and 
anti-apoptotic factors—probably induces apoptosis. This 
hypothesis is supported by the activation of full length 
caspase-9, shifting the balance to cleaved caspase-9. 
Cell apoptosis is eventually induced by activation of the 
intrinsic signaling pathway via caspase-9.
Bad—a further important protein in the apoptosis 
process—stands for Bcl2 antagonist of cell death. This 
protein may develop pro-apoptotic effects due to the het-
erodimerization with anti-apoptotic factors, for instance 
Bcl2, by binding to and thus blocking Bcl2 [37]. After 
stimulation with staurosporine, expression of Bad can-
not any longer be detected by Western blot analysis. A 
possible explanation may be heterodimerization of Bad 
and Bcl2 that further shifts the balance between pro-
apoptotic and anti-apoptotic factors in favor of pro-apop-
totic factors. But degradation pathways at the level of 
transcription, translation level, or protein modification/
clearance would also be conceivable.
Yuste et  al. investigated whether overexpression of 
Bcl2 can rescue cells from staurosporine-induced apop-
tosis. They found that overexpression of Bcl2 increased 
the resistance of cells to staurosporine up to 1  µM. At 
higher doses, cytochrome c release from mitochon-
dria occurred, caspases were activated, and cells died by 
apoptosis.
They also examined whether caspase inhibitors could 
rescue the cells from apoptosis induced by staurosporine. 
For this question they used the noncompetitive inhibi-
tor of caspases z-VAD.fmk. The addition of z-VAD.fmk 
delayed the staurosporine-induced cell death [38].
The Bcl2 protein family plays a key role in the process 
of the intrinsic apoptotic signaling pathway, because dys-
functional Bcl2 protein may result in the development of 
both tumor cells and resistance to chemotherapies [39]. 
As a kinase inhibitor, staurosporine seems to be able to 
Fig. 4 Time-dependent immunoblotting and proof of endogenic expression of Bcl2, BAX, Bad, caspase-8, caspase-9, and ß-actin in colorectal 
carcinoma cells (SW 480) and pancreatic cancer cells (PaTu 8988t and Panc-1) after stimulation with staurosporine
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particularly influence the process of the intrinsic apop-
totic signaling pathway.
In summary, this study showed that staurosporine 
induces apoptosis in pancreatic carcinoma cells via the 
intrinsic signaling pathway. Staurosporine is therefore a 
suitable positive control for in  vitro apoptosis tests for 
the pancreatic carcinoma cell lines PaTu 8988t and Panc-
1. In the colorectal cancer cell line SW 480, stimulation 
with staurosporine did not induce apoptosis.
Conclusion
Modern therapeutic strategies for tumor diseases target 
the efficient modulation of specific signaling and tran-
scription pathways (for instance, VEGF antibodies [40], 
tyrosine kinase inhibitors in the treatment of chronic 
lymphatic leukemia [41], or EGFR antibodies in the 
therapeutic management of advanced colorectal carci-
noma [42]). In this respect, the therapeutic potential of 
protein kinase inhibitors has been repeatedly discussed. 
Pharmaceutical companies increasingly focus on the 
development of new chemotherapies [43]. The approval 
of chemotherapies (for instance, imatinib for treating 
chronic myeloid leukemia, trastuzumab for treating 
breast cancer, or gefitinib and cetuximab for treating 
lung and colorectal cancer) has opened up new possi-
bilities of treating different types of cancer [44]. A large 
number of kinase inhibitors are currently undergoing 
clinical development in both clinical and preclinical 
trials to analyze the potential of these substances for 
medical treatment [45]. However, their side effects and 
toxicity should be closely monitored because kinase 
inhibitors may also modulate important signaling cas-
cades in healthy cells.
Ultimately, the basis and prerequisite of such new 
therapeutic approaches is a comprehensive knowl-
edge of the respective carcinogenesis. The only types 
of cancer that may benefit from therapeutic protein 
kinase inhibitors are diseases marked by upregulation 
of the specific signaling pathways and thus by disturbed 
natural balance between mitosis and apoptosis. Fur-
thermore, a combination therapy of different target-
specific therapeutics will probably be required to avoid 
an increase in the proliferation rate or a decrease in 
the apoptosis rate of cells and thus the development of 
uncontrolled cellular growth [44].
The present work provides insight into the complex-
ity of the Bcl2 family and the apoptotic pathways. Many 
further trials will be required to identify the underly-
ing molecular mechanisms. Identifying and character-
izing cellular receptors and their signal-transduction 
cascades will eventually help establish new therapeutic 
approaches in the treatment of pancreatic carcinoma, 
one of the most aggressive types of all cancers.
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